Sign inSubscribe

target directory

actimmune clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT02584608
Source recordAI-normalized

Phase 2a Study of Interferon Gamma-1b for the Treatment of Autosomal Dominant Type 2 Osteopetrosis

This study is an open label use of ACTIMMUNE for patients with Autosomal Dominant Osteopetrosis Type 2(ADO2). Effects of treatment will be evaluated after 14 weeks on ACTIMMUNE by bone resorption markers. This study will treat 12 patients with ADO2 recruited from Indiana University and Riley Hospital for Children at Indiana University Health.

AI analysis

Indication: Autosomal Dominant Osteopetrosis Type 2

Modality: small molecule

Target: ACTIMMUNE

Sponsor: Indiana University

Source URL: ClinicalTrials.gov

Source updated: Jan 08, 2021

Ingested: May 21, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: ACTIMMUNE

View original source fields

Condition raw: Autosomal Dominant Osteopetrosis Type 2

Condition normalized: Autosomal Dominant Osteopetrosis Type 2

Modality raw: small molecule

Modality normalized: small molecule

Target raw: ACTIMMUNE

Target normalized: ACTIMMUNE

Open report